SNWV
The setup
Sanuwave Health’s second quarter wasn’t a total faceplant, but it wasn’t exactly a victory lap either. Revenue came in at $9.7 million, down 3% from $10.1 million a year ago, with lower UltraMIST system sales doing the most damage.
The good news hiding in the weeds
There’s a reason investors don’t just stare at the top line and go back to sleep: the recurring applicator business kept growing. That matters because recurring revenue can be the financial version of eating vegetables — less glamorous than flashy system sales, but way more useful if you want long-term stability.
Why the market may care
For a smaller healthcare name like Sanuwave, the big question is whether the company can keep converting system placements into steady consumable revenue. If UltraMIST sales stay soft, the stock story gets tougher. If recurring applicator growth keeps building, this starts looking a lot more like a model with legs instead of a one-time product cycle.
Big picture
This is a reminder that investors in medtech names aren’t just betting on a device — they’re betting on the repeat business that comes after it. And that’s usually where the real story lives.